Onyx Pharmaceuticals is seeking out more competitive offers beyond Amgen's $10 billion takeover bid. Mad Money host Jim Cramer says there are better opportunities in the biotech space right now.
Video (8:28)
Onyx Rejects $10 Billion Bid From Amgen
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.